-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
Latest News
-
September 2026: This month in Huntington’s disease research
September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.
-
Proposed Huntington's disease 'biomarker' is not useful, new study suggests
New study shows a blood chemical called '8OHdG' is not a good biomarker for HD. Bad news?
-
Is access to predictive genetic testing for Huntington's disease a problem?
Is access to predictive genetic testing for Huntington's disease a problem? A UBC study says it is.
-
HD Therapeutics Conference 2013 Updates: Day 3
Final day of our coverage of the Huntington's Disease Therapeutics Conference 2013
-
HD Therapeutics Conference 2013 Updates: Day 2
Day 2 of our coverage of the Huntington's Disease Therapeutics Conference
-
Major Roche-Isis deal boosts Huntington's disease gene silencing
'ASO' gene silencing drugs for HD boosted by major deal between Isis Pharmaceuticals and Roche
-
HD Therapeutics Conference 2013 Updates: Day 1
Day 1 of our coverage of the Huntington's Disease Therapeutics Conference
-
Lost in translation? New insights into the making of the Huntington's disease protein
Production of normal-length & extra-long huntingtin is controlled differently. A new way to keep cells healthy in HD?
-
Simple rules for a good night's sleep in Huntington's disease
Prof Jenny Morton's simple rules for a good night's sleep in Huntington's disease
-
Is a new technique set to revolutionize Huntington's disease genetic testing?
A new genetic testing technique for HD has been reported. What does this mean for people at risk or already tested?
-
No surprises in published results from HART study of Huntexil for Huntington's disease
Data from the HART study of Huntexil for HD symptoms now published, but we still need a new, larger trial
HDBuzz Trial Tracker
Show 10 more Show less
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
